COCP - Celsion ThermoDox Spike And Other News: The Good Bad And Ugly Of Biopharma
Celsion jumps up on ThermoDox expectations
Celsion Corporation (CLSN) stock jumped up as the company announced its plan to continue with the process of monitoring the patients for overall survival in the Phase 3 OPTIMA study. The company also stated that a futility threshold observed last month may be attributable to a data maturity issue. Celsion has forwarded the data to NIH for independent evaluation.
Celsion faced a difficult situation past month as the company faced adverse recommendation from the independent Data Monitoring Committee. In its suggestion, the committee had suggested the premature